Can AI detect skin cancer? FDA authorizes use of device to help doctors identify suspicious moles.

18th January 2024 By The Global Heroes Health

The Food and Drug Administration (FDA) has granted authorization for the use of the first artificial intelligence-powered medical device designed to assist doctors in detecting common forms of skin cancer. Developed by DermaSensor, a Miami-based medical device company, the technology does not serve as a screening tool but aids in the evaluation of lesions already identified as suspicious by physicians.

The handheld device employs AI-powered spectroscopy to analyze cellular and subcutaneous characteristics of lesions. Known as DermaSensor, the device utilizes a proprietary algorithm trained on data from over 4,000 malignant and benign lesions, providing real-time results. A "spectral similarity score" is delivered to complement a physician's assessment, offering a high-tech method beyond visual inspection.

Designed for use by primary care physicians and dermatologists, DermaSensor caters to patients aged 40 and above. The device follows a simple process: a doctor identifies a suspicious lesion, the wireless device records and scans it, and the algorithm delivers an immediate assessment. Results include "Investigate Further" for specialist examination and "Monitor" for cases not requiring immediate evaluation.

Beyond detecting melanoma, the deadliest skin cancer, DermaSensor assesses moles for basal cell carcinoma and squamous cell carcinoma. With one in five Americans developing skin cancer by age 70, early detection is crucial. The FDA mandates additional validation testing across diverse demographic groups to enhance the device's reliability and effectiveness. As AI continues to reshape healthcare, DermaSensor represents a milestone in leveraging technology for proactive skin cancer detection and care optimization.